NO880376L - D-gl konjugat-behandling. - Google Patents

D-gl konjugat-behandling.

Info

Publication number
NO880376L
NO880376L NO880376A NO880376A NO880376L NO 880376 L NO880376 L NO 880376L NO 880376 A NO880376 A NO 880376A NO 880376 A NO880376 A NO 880376A NO 880376 L NO880376 L NO 880376L
Authority
NO
Norway
Prior art keywords
conjugate treatment
treatment
lysine
antibody
polymers
Prior art date
Application number
NO880376A
Other languages
English (en)
Norwegian (no)
Other versions
NO880376D0 (no
Inventor
David H Katz
Original Assignee
Quidel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quidel filed Critical Quidel
Publication of NO880376D0 publication Critical patent/NO880376D0/no
Publication of NO880376L publication Critical patent/NO880376L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO880376A 1986-05-30 1988-01-28 D-gl konjugat-behandling. NO880376L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86939386A 1986-05-30 1986-05-30
PCT/US1987/000197 WO1987007145A1 (en) 1986-05-30 1987-02-02 D-gl conjugate therapy

Publications (2)

Publication Number Publication Date
NO880376D0 NO880376D0 (no) 1988-01-28
NO880376L true NO880376L (no) 1988-01-28

Family

ID=25353468

Family Applications (1)

Application Number Title Priority Date Filing Date
NO880376A NO880376L (no) 1986-05-30 1988-01-28 D-gl konjugat-behandling.

Country Status (8)

Country Link
EP (1) EP0272278B1 (de)
JP (1) JPS63503457A (de)
AT (1) ATE90876T1 (de)
CA (1) CA1309558C (de)
DE (1) DE3786334T2 (de)
DK (1) DK33488D0 (de)
NO (1) NO880376L (de)
WO (1) WO1987007145A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4191668A (en) * 1977-02-03 1980-03-04 Scripps Clinic And Research Foundation Induction of immunological tolerance

Also Published As

Publication number Publication date
CA1309558C (en) 1992-10-27
DK33488A (da) 1988-01-25
JPS63503457A (ja) 1988-12-15
NO880376D0 (no) 1988-01-28
ATE90876T1 (de) 1993-07-15
EP0272278B1 (de) 1993-06-23
AU7082987A (en) 1987-12-22
EP0272278A4 (de) 1990-01-08
DE3786334D1 (de) 1993-07-29
DE3786334T2 (de) 1993-12-02
WO1987007145A1 (en) 1987-12-03
EP0272278A1 (de) 1988-06-29
DK33488D0 (da) 1988-01-25
AU604687B2 (en) 1991-01-03

Similar Documents

Publication Publication Date Title
DK442688D0 (da) Fremgangsmaade og praeparat til behandling af non-ige-medierede lidelser
ES2194973T3 (es) Transporte de inmunogenes transepitelial especifico del receptor.
DK651689D0 (da) Oralt autoantigenholdigt praeparat
MY131095A (en) Polyethylene protein conjugates.
DE60039752D1 (de) Herstellung tetravalenter antikörper
DE69133516D1 (de) Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
PT627933E (pt) Supressao "bystander" de doencas autoimunes
ATE245030T1 (de) Antigen-besierende heteropolymere zur behandlung von autoimmunkrankheiten mittels diesen
CY1108318T1 (el) Διεγερση των κυτταρων τ εναντια στα δικα τους αντιγονα με τη χρηση των παραγοντων αποκλεισμου ctla-4
PT84841A (de) Ungesattigte fettsauren enthaltende zubereitungen fuer die synthese von prostaglandinen und hydroxyfettsaueren in biologischen systemen
PT954333E (pt) Receptores soluveis de linfotoxina-beta, anticorpos de receptores de anti-linfotoxina e anticorpos de ligandos de anti-linfotoxina como agentes terapeuticos para o tratamento de doencas imunologicas
DE3781652D1 (de) Zubereitung, geeignet fuer die behandlung von darmstoerungen.
GR3003388T3 (en) Imidazolylguanidine derivatives, process for their preparation and medicines containing them
NO880376L (no) D-gl konjugat-behandling.
ES8206855A1 (es) Un procedimiento para la preparacion de anticuerpos con especialidad frente a antigenos encontrados en los nucleos y nu-cleolos de las celulas humanas cancerosas.
NO986218L (no) FremgangsmÕte til Õ bestemme nµrvµr av hjerneprotein S-100
ES2115582T3 (es) Preparacion y aplicaciones de interferon-gamma.
DE3670307D1 (de) Spezifische mycoplasma-membran-antigene und -antikoerper sowie deren klinische verwendungen.
RU97117537A (ru) Мазь "черная" для лечения арахнозов, дерматомикозов и заболеваний кожи
ES2061718T3 (es) Utilizacion de antigestagenos para la preparacion de medicamentos.
RU96119817A (ru) Способ лечения дисбактериозов кишечника
Burnyasheva et al. On the question of the treatment of urticaria
Ohata Symposium II: Reconstruction of the Trachea Introduction
FR2641182B1 (fr) Appareil de traitement par influence sur les pavillons auriculaires d'un sujet humain ou animal, de champs electriques modules
Tkachiv Clinical and morphological aspects of mammary gland cancer combined therapy with the inter vascular blood irradiation use.; Klyinyiko-morfologyichnyi aspekti kombyinovanogo lyikuvannya raku molochnoyi zalozi z zastosuvannyam vnutrisudinnogo opromyinyuvannya krovyi.